Royalty Pharma plc (RPRX) concluded trading on Thursday at a closing price of $31.21, with 6.59 million shares of worth about $205.69 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 14.07% during that period and on April 10, 2025 the price saw a loss of about -3.28%. Currently the company’s common shares owned by public are about 445.99M shares, out of which, 334.29M shares are available for trading.
Stock saw a price change of -1.82% in past 5 days and over the past one month there was a price change of -4.99%. Year-to-date (YTD), RPRX shares are showing a performance of 22.34% which increased to 5.01% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $24.05 but also hit the highest price of $34.20 during that period. The average intraday trading volume for Royalty Pharma plc shares is 4.86 million. The stock is currently trading -3.04% below its 20-day simple moving average (SMA20), while that difference is down -3.87% for SMA50 and it goes to 8.96% higher than SMA200.
Royalty Pharma plc (NASDAQ: RPRX) currently have 445.99M outstanding shares and institutions hold larger chunk of about 74.37% of that.
The stock has a current market capitalization of $17.99B and its 3Y-monthly beta is at 0.47. PE ratio of stock for trailing 12 months is 16.28, while it has posted earnings per share of $1.92 in the same period. Its PEG reads 1.54 and has Quick Ratio of 1.44 while making debt-to-equity ratio of 1.10. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for RPRX, volatility over the week remained 5.13% while standing at 2.97% over the month.
Stock’s fiscal year EPS is expected to rise by 7.63% while it is estimated to increase by 12.28% in next year. EPS is likely to grow at an annualized rate of 10.55% for next 5-years, compared to annual growth of -21.51% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by UBS on June 03, 2024 offering a Neutral rating for the stock and assigned a target price of $28 to it. Coverage by UBS stated Royalty Pharma plc (RPRX) stock as a Buy in their note to investors on June 14, 2022, suggesting a price target of $47 for the stock. On May 13, 2022, Scotiabank Initiated their recommendations, while on April 27, 2022, Goldman Initiated their ratings for the stock with a price target of $56. Stock get an Overweight rating from JP Morgan on April 14, 2022.
